SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors speculate on an imminent buyout and a potential short squeeze, fueled by high short interest and anticipation surrounding upcoming Phase 3 trial data. The community is actively celebrating the stock's parabolic move to new highs while dismissing bearish sentiment and encouraging long-term holders to maintain their positions as they await major corporate catalysts.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing a significant surge driven by heavy retail buying and option-based gamma hedging ahead of the highly anticipated second-quarter vehicle delivery report. Investors and traders are aggressively debating the sustainability of this price action, with many highlighting the stock's role in broader AI and robotics narratives, while others remain skeptical of its valuation and point to the volatility as a setup for a potential pullback.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing a sharp rally as the market reacts to reports that the Trump administration is exploring direct funding and equity stakes in U.S. drone manufacturers to boost domestic production. The community is actively debating the stock's valuation and long-term potential, weighing the company's strong defense backlog and role in autonomous systems against broader market volatility and uncertainty surrounding government procurement cycles.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is surging as market sentiment shifts toward the Physical AI theme, with investors increasingly viewing the company as a foundational infrastructure provider for robotics, industrial automation, and autonomous navigation. The community is actively discussing the stock's role in the supply chain for advanced machinery, bolstered by strategic partnerships and successful operational deployments ahead of major global events.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the focus of market attention following its massive 8 billion dollar acquisition of Iridium Communications, a deal that integrates launch capabilities with a global satellite network and recurring revenue streams. The community is actively debating the strategic shift toward becoming a vertically integrated space powerhouse, with many investors viewing the move as a major long-term catalyst for growth alongside the anticipation of the Neutron launch.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack in the Box is drawing significant attention from retail traders who are targeting the stock for a potential short squeeze, fueled by high short interest and a relatively small share float. Community discourse is heavily focused on comparing it to other high-profile meme stock plays, with investors debating the company's turnaround potential and debt load versus its current valuation.

SharonAI Holdings, Inc. operates as a holding company that develops and delivers GPU cloud computing and AI solutions. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending due to significant institutional backing from Leopold Aschenbrenner and a massive strategic AI infrastructure contract that has sparked community debate over its low-float potential and valuation. Investors are actively discussing the stock's long-term upside compared to infrastructure peers, with many focused on institutional positioning flow as a signal for sustained growth.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently a focal point for the community due to significant volatility, fueled by discussions around potential short squeeze setups, upcoming Russell 2000 index inclusion, and a steady stream of defense sector contracts and acquisitions. Investors are actively debating whether the recent price decline represents a long-term accumulation opportunity supported by strong autonomous defense tailwinds or a risk of further dilution and technical breakdown.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing a surge in volatility driven by a major borrow rate spike exceeding 100% and high short interest, fueling intense community speculation about a potential short squeeze. Traders are reacting to a combination of technical reversal signals, robotaxi partnership news, and ongoing skepticism regarding the company's long-term dilution and production scaling.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions is experiencing intense community focus following a new share offering, which has sparked a debate between those concerned about supply-side dilution and those betting on the company's long-term leadership in AI grid infrastructure. Investors remain heavily divided, weighing short-term pressure from the overhang against the firm's explosive backlog and its status as a critical bottleneck provider for data center energy demands.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Key PointsIntellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies...

This Stock Is Up 58% This Year. Is It too Late to Buy?

Key PointsOne of Intellia Therapeutics' leading candidates recently aced a phase 3 study...

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Nasdaq, S&P 500 Futures Cheer Iran Breakthrough, Crude Slides: Why SPCX, NVDA, RKLB, ASTS, RCAT, NTLA Are Keeping Traders Hooked

Equity

Despite the rebound in futures, Stocktwits data showed retail sentiment has moved to ‘bearish’ on SPY and QQQ.

Why Is NTLA Stock Jumping 5% Premarket Today?

Intellia unveiled additional Phase 3 data for its CRISPR-based HAE treatment, Lonvo-z.

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now? 

NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets. 

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

NTLAIntellia Therapeutics Inc

Fundamentals

Latest NTLA News